Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA, Versage EM, Richert JR, Axtell RC, et al. Neurology. 2012 May 9. PMID: 22573631. Abstract CommentRecommendBookmarkWatch